BOK Financial Private Wealth Inc. Sells 374 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

BOK Financial Private Wealth Inc. trimmed its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 15.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,983 shares of the pharmaceutical company’s stock after selling 374 shares during the period. BOK Financial Private Wealth Inc.’s holdings in Vertex Pharmaceuticals were worth $799,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Concurrent Investment Advisors LLC lifted its stake in shares of Vertex Pharmaceuticals by 35.3% during the 3rd quarter. Concurrent Investment Advisors LLC now owns 2,072 shares of the pharmaceutical company’s stock worth $964,000 after acquiring an additional 541 shares during the last quarter. Portside Wealth Group LLC lifted its position in shares of Vertex Pharmaceuticals by 10.7% during the third quarter. Portside Wealth Group LLC now owns 2,005 shares of the pharmaceutical company’s stock worth $932,000 after purchasing an additional 193 shares during the last quarter. Capital Performance Advisors LLP purchased a new stake in shares of Vertex Pharmaceuticals during the third quarter valued at $39,000. Leavell Investment Management Inc. grew its stake in Vertex Pharmaceuticals by 16.7% in the 3rd quarter. Leavell Investment Management Inc. now owns 5,509 shares of the pharmaceutical company’s stock worth $2,562,000 after acquiring an additional 790 shares in the last quarter. Finally, CWA Asset Management Group LLC bought a new position in Vertex Pharmaceuticals in the third quarter worth approximately $2,933,000. 90.96% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 244 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $455.06, for a total value of $111,034.64. Following the sale, the executive vice president now owns 67,695 shares of the company’s stock, valued at $30,805,286.70. The trade was a 0.36 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last three months, insiders have sold 1,084 shares of company stock worth $505,512. Insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Trading Up 0.5 %

VRTX opened at $488.29 on Friday. Vertex Pharmaceuticals Incorporated has a one year low of $377.85 and a one year high of $519.88. The stock has a market capitalization of $125.39 billion, a PE ratio of -221.95, a P/E/G ratio of 2.11 and a beta of 0.41. The business’s 50 day moving average price is $448.27 and its 200 day moving average price is $461.32. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.35 and a current ratio of 2.69.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Monday, February 10th. The pharmaceutical company reported $3.54 EPS for the quarter, missing analysts’ consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. As a group, equities research analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on VRTX. BMO Capital Markets set a $545.00 price objective on shares of Vertex Pharmaceuticals in a report on Friday, January 31st. Royal Bank of Canada increased their price objective on Vertex Pharmaceuticals from $407.00 to $408.00 and gave the company a “sector perform” rating in a report on Thursday, February 20th. Bank of America decreased their price objective on Vertex Pharmaceuticals from $545.00 to $522.00 and set a “buy” rating for the company in a report on Thursday, December 19th. Needham & Company LLC reiterated a “hold” rating on shares of Vertex Pharmaceuticals in a report on Tuesday, February 11th. Finally, HC Wainwright reiterated a “buy” rating and set a $550.00 price objective on shares of Vertex Pharmaceuticals in a report on Tuesday, February 11th. Eleven research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $506.70.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.